StoneX Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

StoneX Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$758K	Buy	5,018 +2,604	+108%	+$352K	0.03%	427
2026 Q1	$305K	Buy	2,414 +576	+31%	+$71.9K	0.02%	565
2025 Q4	$224K	Sell	1,838 -19,325	-91%	-$2.22M	0.01%	829
2025 Q3	$2.12M	Sell	21,163 -1,161	-5%	-$105K	0.09%	184
2025 Q2	$1.85M	Sell	22,324 -2,151	-9%	-$172K	0.09%	191
2025 Q1	$1.98M	Sell	24,475 -2,904	-11%	-$260K	0.11%	177
2024 Q4	$2.47M	Buy	27,379 +21,221	+345%	+$2.06M	0.14%	143
2024 Q3	$608K	Buy	6,158 +40	+0.7%	+$3.93K	0.04%	306
2024 Q2	$567K	Sell	6,118 -2,897	-32%	-$260K	0.05%	310
2024 Q1	$855K	Buy	9,015 +3,500	+63%	+$325K	0.08%	220
2023 Q4	$492K	Sell	5,515 -4,120	-43%	-$306K	0.05%	301
2023 Q3	$704K	Buy	9,635 +1,780	+23%	+$142K	0.08%	232
2023 Q2	$654K	Buy	7,855 +407	+5%	+$34K	0.07%	251
2023 Q1	$568K	Sell	7,448 -114	-2%	-$9.46K	0.06%	277
2022 Q4	$628K	Sell	7,562 -3,755	-33%	-$304K	0.07%	244
2022 Q3	$898K	Buy	11,317 +4,190	+59%	+$353K	0.12%	161
2022 Q2	$529K	Sell	7,127 -445	-6%	-$33.4K	0.06%	277
2022 Q1	$681K	Buy	7,572 +340	+5%	+$31.4K	0.05%	296
2021 Q4	$810K	Buy	7,232 +132	+2%	+$15.9K	0.09%	205
2021 Q3	$893K	Sell	7,100 -563	-7%	-$72.5K	0.13%	172
2021 Q2	$1.04M	Buy	7,663 +86	+1%	+$11.3K	0.15%	144
2021 Q1	$1.03M	Sell	7,577 -1,401	-16%	-$210K	0.18%	108
2020 Q4	$1.26M	Buy	8,978 +94	+1%	+$12K	0.28%	66
2020 Q3	$990K	Buy	8,884 +1,008	+13%	+$113K	0.32%	72
2020 Q2	$882K	Sell	7,876 -252	-3%	-$24.8K	0.33%	76
2020 Q1	$629K	Buy	8,128 +1,652	+26%	+$146K	0.33%	90
2019 Q4	$616K	Sell	6,476 -252	-4%	-$21.8K	0.25%	119
2019 Q3	$513K	Buy	6,728 +30	+0.4%	+$2.49K	0.32%	105
2019 Q2	$587K	Sell	6,698 -396	-6%	-$33.8K	0.38%	84
2019 Q1	$642K	Buy	7,094 +58	+0.8%	+$4.93K	0.49%	70
2018 Q4	$505K	Sell	7,036 -1,249	-15%	-$101K	0.49%	73
2018 Q3	$794K	Buy	8,285 +394	+5%	+$38.2K	0.59%	50
2018 Q2	$751K	Sell	7,891 -436	-5%	-$40.1K	0.65%	43
2018 Q1	$731K	Buy	8,327 +2,413	+41%	+$220K	0.7%	34
2017 Q4	$502K	Sell	5,914 -1,388	-19%	-$116K	0.52%	57
2017 Q3	$632K	Buy	7,302 +22	+0.3%	+$1.76K	0.79%	36
2017 Q2	$562K	Buy	+7,280	New	+$516K	0.18%	192

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

StoneX Group's XBI Position: Q2 2026 in Review

StoneX Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 108% in Q2 2026, buying an estimated $352K and bringing the position to 5,018 shares worth $758K. The position accounts for 0.03% of the portfolio, ranked #427.

StoneX Group first reported a position in XBI in Q2 2017 and has held it in 37 quarters since. The position peaked at $2.47M in Q4 2024. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

StoneX Group held 5,018 shares of State Street SPDR S&P Biotech ETF worth $758K as of Q2 2026.
StoneX Group bought 2,604 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $352K.
State Street SPDR S&P Biotech ETF made up 0.03% of StoneX Group's portfolio in Q2 2026, its #427 holding.
StoneX Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 37 quarters since.
StoneX Group's State Street SPDR S&P Biotech ETF position peaked at $2.47M in Q4 2024.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.